Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Bonus News from MarketBeat.com
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?Reported by Jeffrey Neal Johnson. Article Posted: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: Elon Musk’s $1 Quadrillion AI IPO
In the world of investing, stability is a prized commodity. Few firms illustrate that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That reputation makes the company’s recent stock weakness all the more notable.
For a moment…
Forget about Trump’s ties to Israel.
Forget about reports of Iran’s nuclear program.
Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. Click here to find out what it is.
Abbott Laboratories’ stock price briefly touched a 52-week low, closing just above $100 in late March. The sharp pullback has left some investors asking whether the company’s long-term foundation is eroding. A closer look suggests a potential disconnect between market sentiment and operational reality. The key question: Is the market’s pessimism justified, or has a meaningful value opportunity opened for long-term investors? Separating the Signal From the NoiseAbbott’s recent decline stems from two distinct pressures. The first is internal: its Nutrition segment. Abbott’s fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in Nutrition, driven mainly by market-share losses in the U.S. pediatric business and pricing dynamics that constrained volume. Management has been candid about the issue and outlined a turnaround plan. CEO Robert B. Ford described price and promotion initiatives and a pipeline of at least eight new product launches in 2026, with management forecasting a return to growth in the second half of the year. The second factor is external and broader: a rotation of capital across the market. As investors chase higher returns in higher-beta areas—like AI stocks and the energy sector—defensive sectors such as healthcare can be sold off. This rotation has pressured fundamentally sound healthcare names, including Abbott, for reasons largely unrelated to each company’s operational performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile Nutrition works through a short-term recovery, Abbott’s core remains robust—led by its largest and most profitable segment: Medical Devices. That division accelerated, posting 10.4% organic growth in the most recent quarter. Abbott’s diversified model helps offset isolated weakness in Nutrition, and the company’s true strength is visible in its higher-performing areas.
Medical Devices: The Medical Devices business is firing on multiple cylinders, driven by innovation across critical-care categories. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) remains a major growth engine. The franchise, which reduces the need for routine fingersticks, generated more than $7.5 billion in sales in 2025 and is a primary driver of Abbott’s sustained success. Cardiovascular Leadership: Abbott is a leader in cardiovascular health. Its Electrophysiology business grew at a double-digit rate, and the Structural Heart business posted strong organic growth of 8.7%. This strength is supported by best-in-class products such as MitraClip and TriClip for minimally invasive valve repair and a pipeline of innovations, including the recently FDA-approved Volt PFA System for treating atrial fibrillation. Abbott is also positioning itself for future growth through the acquisition of Exact Sciences, a leader in cancer screening and diagnostics best known for its non-invasive colon cancer test, Cologuard. That deal would immediately expand Abbott’s addressable market into the fast-growing, multi-billion-dollar cancer diagnostics space and add a high-growth vertical likely to contribute meaningfully to revenue over time. Wall Street appears to share a cautiously optimistic view. Analysts maintain a Moderate Buy consensus rating on the stock, with an average 12-month price target of $135.47—implying more than 30% upside from current levels and suggesting many analysts view the shares as undervalued. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on reliable income, Abbott’s dividend is a standout feature. Abbott is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have increased their dividend for at least 50 consecutive years. That track record reflects a deep commitment to returning capital to shareholders through multiple market cycles. The recent decline in Abbott’s stock price translates into a higher yield for new investors—roughly 2.5% at current levels—letting investors lock in a stronger income rate from a historically reliable payer. The dividend also appears secure: the payout ratio is about 68% of earnings but only about 37% of cash flow, indicating Abbott generates more than enough cash to cover distributions with room for future increases. A Disconnect Between Price and ValueCurrent market sentiment looks somewhat disconnected from Abbott’s business reality. Temporary headwinds in a single division and broader market rotation have pressured the stock price, yet Abbott’s fundamental growth drivers are accelerating. Its dominant Medical Devices division continues to deliver, the dividend remains a pillar of reliability, and strategic catalysts—like the Exact Sciences acquisition—could add material long-term growth. For investors with a multiyear horizon, the current valuation highlights a gap between market price and intrinsic value that may present a compelling opportunity. |
